Teva-Ivax Merger Puts Spotlight On Authorized Generics

Law360, New York (July 28, 2005, 12:00 AM EDT) -- Teva Pharmaceutical Industries Ltd.’s $7.4 billion purchase of Ivax Corp. will once again propel the Israeli drug maker past Novartis as a leader in the $58-billion worldwide market for generic drugs. But the deal will force Teva to take a stand on the controversial practice of “authorized generics,” analysts say.

The merger gives Teva, which sells generic versions of AstraZeneca Plc's Prilosec ulcer drug and Purdue Pharma LP's Oxycontin painkiller, Ivax's rights to generic versions of Pfizer Inc.'s Zoloft antidepressant and GlaxoSmithKline Plc's Zofran for nausea....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.